The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications
Identifieur interne : 001822 ( Main/Exploration ); précédent : 001821; suivant : 001823The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications
Auteurs : V. S. Kosti ; J. Marinkovi ; M. Svetel ; E. Stefanova ; S. Przedborski [États-Unis]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2002-01-20.
English descriptors
- KwdEn :
Abstract
The aim of this study was to ascertain whether the stage of Parkinson’s disease (PD) (according to the Hoehn and Yahr staging system) would affect the length of time between the introduction of levodopa therapy and appearance of levodopa‐associated motor complications. Forty patients with clinically definite PD were studied. In all, clinical and therapeutic data were collected from the time of diagnosis to the time of levodopa‐associated motor complications (i.e. dyskinesia, motor fluctuations). In 17 patients, levodopa could be started in Hoehn and Yahr stage I (H&Y‐I; 16.2 months after the onset of PD), whilst in 13 patients levodopa could be started in H&Y‐II (19.6 months after the onset of the disease) and in 10 in H&Y‐III (45.1 months after the onset of PD). Cox proportional hazard regression model shows that the PD patients in whom the initial levodopa treatment was introduced at stage III develop both dyskinesias and motor fluctuations significantly earlier than the patients whose levodopa started in stage I and II of PD. The median interval to develop dyskinesias was 66, 72 and 24 months for patients in whom levodopa was introduced in stage I, II and III, respectively. These values were 64, 55 and 14 months for motor fluctuations. These findings add to the clinical arguments that favour an essential role of severity of PD at levodopa initiation as a risk factor for the development of levodopa‐associated motor complications.
Url:
DOI: 10.1046/j.1468-1331.2002.00346.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications</title><author><name sortKey="Kosti, V S" sort="Kosti, V S" uniqKey="Kosti V" first="V. S." last="Kosti">V. S. Kosti</name></author><author><name sortKey="Marinkovi, J" sort="Marinkovi, J" uniqKey="Marinkovi J" first="J." last="Marinkovi">J. Marinkovi</name></author><author><name sortKey="Svetel, M" sort="Svetel, M" uniqKey="Svetel M" first="M." last="Svetel">M. Svetel</name></author><author><name sortKey="Stefanova, E" sort="Stefanova, E" uniqKey="Stefanova E" first="E." last="Stefanova">E. Stefanova</name></author><author><name sortKey="Przedborski, S" sort="Przedborski, S" uniqKey="Przedborski S" first="S." last="Przedborski">S. Przedborski</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A2DFCB36EA77102D7FCDE4BAC126CBE29ACEA926</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1046/j.1468-1331.2002.00346.x</idno><idno type="url">https://api.istex.fr/document/A2DFCB36EA77102D7FCDE4BAC126CBE29ACEA926/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001638</idno><idno type="wicri:Area/Main/Curation">001404</idno><idno type="wicri:Area/Main/Exploration">001822</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications</title><author><name sortKey="Kosti, V S" sort="Kosti, V S" uniqKey="Kosti V" first="V. S." last="Kosti">V. S. Kosti</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Marinkovi, J" sort="Marinkovi, J" uniqKey="Marinkovi J" first="J." last="Marinkovi">J. Marinkovi</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Svetel, M" sort="Svetel, M" uniqKey="Svetel M" first="M." last="Svetel">M. Svetel</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Stefanova, E" sort="Stefanova, E" uniqKey="Stefanova E" first="E." last="Stefanova">E. Stefanova</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Przedborski, S" sort="Przedborski, S" uniqKey="Przedborski S" first="S." last="Przedborski">S. Przedborski</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neurological Institute, College of Physicians and Surgeons, Columbia University, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford UK</pubPlace><date type="published" when="2002-01-20">2002-01-20</date><biblScope unit="volume">9</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="9">9</biblScope><biblScope unit="page" to="14">14</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">A2DFCB36EA77102D7FCDE4BAC126CBE29ACEA926</idno><idno type="DOI">10.1046/j.1468-1331.2002.00346.x</idno><idno type="ArticleID">ENE346</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson’s disease</term><term>levodopa</term><term>motor complications</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to ascertain whether the stage of Parkinson’s disease (PD) (according to the Hoehn and Yahr staging system) would affect the length of time between the introduction of levodopa therapy and appearance of levodopa‐associated motor complications. Forty patients with clinically definite PD were studied. In all, clinical and therapeutic data were collected from the time of diagnosis to the time of levodopa‐associated motor complications (i.e. dyskinesia, motor fluctuations). In 17 patients, levodopa could be started in Hoehn and Yahr stage I (H&Y‐I; 16.2 months after the onset of PD), whilst in 13 patients levodopa could be started in H&Y‐II (19.6 months after the onset of the disease) and in 10 in H&Y‐III (45.1 months after the onset of PD). Cox proportional hazard regression model shows that the PD patients in whom the initial levodopa treatment was introduced at stage III develop both dyskinesias and motor fluctuations significantly earlier than the patients whose levodopa started in stage I and II of PD. The median interval to develop dyskinesias was 66, 72 and 24 months for patients in whom levodopa was introduced in stage I, II and III, respectively. These values were 64, 55 and 14 months for motor fluctuations. These findings add to the clinical arguments that favour an essential role of severity of PD at levodopa initiation as a risk factor for the development of levodopa‐associated motor complications.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region><settlement><li>New York</li></settlement><orgName><li>Université Columbia</li></orgName></list><tree><noCountry><name sortKey="Kosti, V S" sort="Kosti, V S" uniqKey="Kosti V" first="V. S." last="Kosti">V. S. Kosti</name><name sortKey="Marinkovi, J" sort="Marinkovi, J" uniqKey="Marinkovi J" first="J." last="Marinkovi">J. Marinkovi</name><name sortKey="Stefanova, E" sort="Stefanova, E" uniqKey="Stefanova E" first="E." last="Stefanova">E. Stefanova</name><name sortKey="Svetel, M" sort="Svetel, M" uniqKey="Svetel M" first="M." last="Svetel">M. Svetel</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Przedborski, S" sort="Przedborski, S" uniqKey="Przedborski S" first="S." last="Przedborski">S. Przedborski</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001822 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001822 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A2DFCB36EA77102D7FCDE4BAC126CBE29ACEA926
|texte= The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications
}}
| This area was generated with Dilib version V0.6.23. |  |